LongBio Pharma (Suzhou) (1779) Stock Overview
Engages in discovery and development of biopharmaceuticals that targets allergic and autoimmune diseases in the People's Republic of China and Hong Kong. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
1779 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
LongBio Pharma (Suzhou) Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$142.80 |
| 52 Week High | HK$158.00 |
| 52 Week Low | HK$116.10 |
| Beta | 0 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 8.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1779 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 0.6% | 1.5% | -2.2% |
| 1Y | n/a | -5.7% | 4.1% |
Return vs Industry: Insufficient data to determine how 1779 performed against the Hong Kong Biotechs industry.
Return vs Market: Insufficient data to determine how 1779 performed against the Hong Kong Market.
Price Volatility
| 1779 volatility | |
|---|---|
| 1779 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 16.0% |
| 10% least volatile stocks in HK Market | 3.6% |
Stable Share Price: 1779's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: Insufficient data to determine 1779's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 85 | Heng Liu | www.longbio.com |
LongBio Pharma (Suzhou) Co., Ltd. engages in discovery and development of biopharmaceuticals that targets allergic and autoimmune diseases in the People's Republic of China and Hong Kong. The company's products includes LP-003, an anti-IgE antibody with novel sequencing; LP-005, bi-functional antibody fusion protein; LP-00A, a bi-functional antibody for allergic diseases; LP-00C, a bi-functional antibody or fusion protein for B-cell mediated autoimmune diseases; and LP-00D, a bi-functional antibody or fusion protein complement inhibitor for specific tissues,organs and indications. The company was founded in 2020 and is based in Changshu, China.
LongBio Pharma (Suzhou) Co., Ltd. Fundamentals Summary
| 1779 fundamental statistics | |
|---|---|
| Market cap | HK$10.39b |
| Earnings (TTM) | -HK$203.52m |
| Revenue (TTM) | n/a |
Is 1779 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1779 income statement (TTM) | |
|---|---|
| Revenue | CN¥0 |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥0 |
| Other Expenses | CN¥175.58m |
| Earnings | -CN¥175.58m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.37 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 24.9% |
How did 1779 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/18 15:13 |
| End of Day Share Price | 2026/06/18 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
LongBio Pharma (Suzhou) Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.